Keyphrases
Antiepileptogenic
9%
Baclofen
31%
Baclofen Withdrawal
9%
Benzodiazepines
28%
Blood Samples
14%
Brain Uptake
14%
Canine
22%
Clinical Pharmacology
10%
Clinical Tolerance
14%
Cysteine
9%
Diazepam
11%
Drug Exposure
10%
Early Seizures
14%
Early-life Exposure
14%
Epilepsy
32%
Established Status Epilepticus
33%
Fosphenytoin
38%
Glutathione
19%
Healthy Volunteers
14%
High Dose
10%
Hypoglycemia
9%
Infantile Spasms
14%
Intravenous Administration
18%
Lateral Fluid Percussion
29%
Levetiracetam
43%
Loading Dose
9%
N-acetylcysteine
58%
Nave
11%
New-onset Refractory Status Epilepticus (NORSE)
18%
Older Adults
12%
P-glycoprotein (P-gp)
12%
Parkinson's Disease
21%
Pharmacodynamics
11%
Pharmacokinetics
77%
Phenytoin
18%
Post-traumatic Epilepsy
18%
Rat Model
15%
Route of Administration
9%
Seizure
17%
Seizure Cessation
9%
Seizure Emergencies
9%
Sodium Selenite
14%
Status Epilepticus
43%
Status Epilepticus Treatment
27%
Temporal Lobe
10%
Tolerability
32%
Traumatic Brain Injury
18%
Treatment Trials
27%
Ursodeoxycholic Acid
9%
Valproic Acid
18%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylcysteine
58%
Anticonvulsive Agent
11%
Antioxidant
8%
Automutilation
7%
Baclofen
36%
Benzodiazepine
25%
Bioavailability
7%
Biological Marker
15%
Biomarker Study
7%
Brexanolone
10%
Buprenorphine
7%
Canine Model
7%
Celastrol
7%
Clinical Trial
9%
Cysteine
9%
Diazepam
16%
Dipeptidyl Carboxypeptidase
10%
Drug Administration
11%
Drug Development
7%
Edaravone
7%
Epileptic State
75%
Focal Epilepsy
7%
Fosphenytoin Sodium
37%
Gaucher's Disease
8%
Glutathione
25%
Hypoglycemia
14%
Infantile Spasm
14%
Intubation
8%
Ketamine
7%
Levetiracetam
42%
Lorazepam
8%
Methadone
7%
Midazolam
8%
Muscle Spasm
7%
Normal Human
15%
Parkinson's Disease
21%
Pharmacodynamics
20%
Pharmacokinetics
100%
Phenytoin
19%
Plasma Protein
7%
Prodrug
10%
Randomized Controlled Trial
7%
Rat Model
14%
Repurposing
7%
Saquinavir
7%
Sodium Valproate
27%
Tolerability
32%
Topiramate
7%
Traumatic Brain Injury
15%
Ursodeoxycholic Acid
7%